### Chile: Tuberculosis Profile

#### Population 2017: 18 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2017</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>0.43 (0.41–0.44)</td>
<td>2.4 (2.3–2.4)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.079 (0.04–0.13)</td>
<td>0.44 (0.22–0.73)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>3.2 (2.7–3.6)</td>
<td>17 (15–20)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>0.51 (0.31–0.77)</td>
<td>2.8 (1.7–4.3)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>0.074 (0.049–0.1)</td>
<td>0.41 (0.27–0.57)</td>
</tr>
</tbody>
</table>

#### Estimated TB incidence by age and sex (thousands)*, 2017

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Females</th>
<th>Males</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14 years</td>
<td>0.15 (0.12–0.19)</td>
<td>0.17 (0.13–0.2)</td>
<td>0.32 (0.27–0.37)</td>
</tr>
<tr>
<td>&gt; 14 years</td>
<td>1 (0.77–1.2)</td>
<td>1.8 (1.4–2.2)</td>
<td>2.8 (2.4–3.3)</td>
</tr>
<tr>
<td>Total</td>
<td>1.1 (0.91–1.4)</td>
<td>2 (1.6–2.4)</td>
<td>3.2 (2.7–3.6)</td>
</tr>
</tbody>
</table>

#### TB case notifications, 2017

- Total cases notified: 2,806
- Total new and relapse: 2,740
  - % with known HIV status: 83%
  - % bacteriologically confirmed among pulmonary: 91%

#### Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2017: 87% (75–100)
- TB patients facing catastrophic total costs: 0.16 (0.13–0.19)

#### Incidence

- Notified cases by age group and sex, 2017

#### Treatment success rate and cohort size

- New and relapse cases registered in 2016: 79% (2,548)
- Previously treated cases, excluding relapse, registered in 2016: 54% (240)
- MDR/RR-TB cases started on second-line treatment in 2015: 37% (19)

#### TB preventive treatment, 2017

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 261 (11%)
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

#### TB financing, 2018

- National TB budget (US$ millions): 3

---

*Ranges represent uncertainty intervals

**MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

***Includes cases with unknown previous TB treatment history

****Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-06-22